Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 6 vom: 12. Sept., Seite 1410-1412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Brien, Thomas R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
82115-62-6 |
|---|
| Anmerkungen: |
Date Completed 24.09.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308867734 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308867734 | ||
| 003 | DE-627 | ||
| 005 | 20231225132649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308867734 | ||
| 035 | |a (NLM)32301957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Brien, Thomas R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a MERS-CoV | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a innate immunity | |
| 650 | 4 | |a severe acute respiratory syndrome | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 700 | 1 | |a Thomas, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Sarah S |e verfasserin |4 aut | |
| 700 | 1 | |a Prokunina-Olsson, Ludmila |e verfasserin |4 aut | |
| 700 | 1 | |a Donnelly, Raymond P |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Rune |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 6 vom: 12. Sept., Seite 1410-1412 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:6 |g day:12 |g month:09 |g pages:1410-1412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 6 |b 12 |c 09 |h 1410-1412 | ||